T2 Biosystems (TTOO) Earning Somewhat Positive Press Coverage, Report Finds
Media stories about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. T2 Biosystems earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 45.661058565316 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of T2 Biosystems (TTOO) traded up 5.13% during mid-day trading on Monday, hitting $4.51. The company’s stock had a trading volume of 124,231 shares. The stock’s 50 day moving average price is $4.09 and its 200 day moving average price is $4.11. T2 Biosystems has a 52-week low of $2.50 and a 52-week high of $8.04. The company’s market cap is $138.75 million.
T2 Biosystems (NASDAQ:TTOO) last released its quarterly earnings results on Thursday, August 3rd. The medical equipment provider reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.01). The firm had revenue of $0.96 million for the quarter, compared to the consensus estimate of $0.79 million. T2 Biosystems had a negative net margin of 1,473.71% and a negative return on equity of 178.83%. Equities analysts forecast that T2 Biosystems will post ($1.92) EPS for the current year.
A number of analysts recently commented on the company. Zacks Investment Research lowered T2 Biosystems from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. ValuEngine upgraded T2 Biosystems from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 13th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $6.75.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/25/t2-biosystems-ttoo-earning-somewhat-positive-press-coverage-report-finds.html.
About T2 Biosystems
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.